BioMarin CEO JJ Bienaimé joins Yahoo Finance Live’s Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biotechnology, biotech stocks, and key takeaways from JPMorgan’s annual health care conference.
For example, Novavax (NASDAQ: NVAX) soared 2,700% in 2020. Of course, it's impossible to predict with 100% certainty which companies will succeed in the vaccine race -- and whether their share prices will skyrocket. Gritstone Bio (NASDAQ: GRTS) is developing an mRNA vaccine candidate.
The recent surge in COVID-19 cases caused by the new and more contagious omicron variant of the coronavirus has taught us at least one thing: There's still a dire need for effective vaccines against this potentially deadly disease. Several companies are still looking to enter the coronavirus vaccine market, even though Pfizer and Moderna currently dominate it. One biotech that is slowly advancing a coronavirus vaccine candidate is Vaxart (NASDAQ: VXRT).